NCT06334016
Evaluating the Delivery and Effects of THC Vaping Liquids in the Bloodstream
At risk: Primary completion moved 9 months later, primary endpoint(s) modified.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 12 versions: 12 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary completion pushed from Mar 1, 2028 to Dec 1, 2028 Show 4 more changesShow less
- Primary endpoint(s) modified
- Start date pushed from Oct 15, 2026 to Dec 15, 2026
- Eligibility criteria expanded, about 1 word
- Study completion pushed from Mar 1, 2028 to Dec 1, 2029
- Notable Start date: Sep 15, 2026 to Oct 15, 2026
- Eligibility criteria expanded, about 28 words
- Secondary endpoints: details revised at 4 of 8 entries
- Study description expanded, about 9 words
- Notable Start date: Jul 15, 2026 to Sep 15, 2026v10
- Notable Start date: May 15, 2026 to Jul 15, 2026v9
- Notable Start date: Mar 15, 2026 to May 15, 2026v8
Show 6 earlier versionsHide 6 earlier versions
- Minor Start date: Feb 15, 2026 to Mar 15, 2026v7
- Notable Start date: Nov 15, 2025 to Feb 15, 2026v6
- Notable Start date: Sep 15, 2025 to Nov 15, 2025v5
- Notable Start date: Jul 27, 2025 to Sep 15, 2025v4
- Notable Start date: May 27, 2025 to Jul 27, 2025v3
- Notable Start date: Mar 27, 2025 to May 27, 2025v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (7)
Show 2 moreShow less
Arms and interventions
Participants complete 3 vaping sessions separated by 7-14 days on study: * VISIT 1: Participants vape placebo nicotine for 10 minutes, followed by THC for 10 minutes, and then placebo nicotine again for 10 minutes. * VISIT 2: Participants vape nicotine for 10 minutes, followed by THC for 10 minutes, and then placebo nicotine for 10 minutes. * VISIT 3: Participants vape placebo nicotine for 10 minutes, followed by THC for 10 minutes, and then nicotine for 10 minutes. All participants also undergo blood sample collection throughout the trial.
Participants complete 3 vaping sessions separated by 7-14 days on study: * VISIT 1: Participants vape nicotine for 10 minutes, followed by THC for 10 minutes, and then placebo nicotine for 10 minutes. * VISIT 2: Participants vape placebo nicotine for 10 minutes, followed by THC for 10 minutes, and then nicotine for 10 minutes. * VISIT 3: Participants vape placebo nicotine for 10 minutes, followed by THC for 10 minutes, and then placebo nicotine again for 10 minutes. All participants also undergo blood sample collection throughout the trial.
Participants complete 3 vaping sessions separated by 7-14 days on study: * VISIT 1: Participants vape placebo nicotine for 10 minutes, followed by THC for 10 minutes, and then nicotine for 10 minutes. * VISIT 2: Participants vape placebo nicotine for 10 minutes, followed by THC for 10 minutes, and then placebo nicotine again for 10 minutes. * VISIT 3: Participants vape nicotine for 10 minutes, followed by THC for 10 minutes, and then placebo nicotine for 10 minutes. All participants also undergo blood sample collection throughout the trial.
Procedures: Biospecimen Collection
Drugs: Cannabis sativa Extract, Nicotine, Placebo Administration
Other: Questionnaire Administration
Sites
1 site in 1 country
- Roswell Park Cancer InstituteBuffalo, New York, United States